You must log in to view this page.

Cognition Therapeutics Inc. – Filings and Transcripts

NASDAQ: CGTX
Share price (3/18/26): $1.10
Market cap (3/18/26): $97.1 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 09/30/25 Q3

ended 06/30/25 Q2

ended 03/31/25 Q1

ended 12/31/24 FY 2024

ended 09/30/24 Q3

Prospectuses and Registrations Filter

Shelf registration

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Registration of securities for employees

Registration of securities for employees

Ownership Filter

Doyle John Brendan

Caggiano Anthony

Doyle John Brendan

News Filter

Advancing Zervimesine (CT1812) for Dementia With Lewy Bodies (DLB) Psychosis

Completes Type C Meeting With FDA for Zervimesine (CT1812) in Dementia With Lewy Bodies

Material Definitive Agreement, Termination of Material Definitive Agreement

Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs

Investor Presentation

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Notice of effectiveness

Scanned paper annual report submission

Scanned paper annual report submission

Notice of effectiveness

Correspondence with the SEC